Oncología Traslacional
ONCTRAS
Medical University of South Carolina
Charleston, Estados UnidosPublicacións en colaboración con investigadores/as de Medical University of South Carolina (7)
2024
-
A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial
Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809
-
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 187, pp. 128-138
2023
-
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
European Journal of Cancer, Vol. 189
-
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Cancer, Vol. 129, Núm. 12, pp. 1846-1855
2022
-
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients – Pooled analysis from the PRIMA trial
Gynecologic Oncology, Vol. 166, Núm. 3, pp. 494-502
2020
-
Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer
Obstetrical and Gynecological Survey
2019
-
Niraparib in patients with newly diagnosed advanced ovarian cancer
New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402